Gossamer Bio is back in focus after its fair value estimate was trimmed from $4.46 to $3.86, a shift that has caught the attention of investors tracking the stock. The change sits alongside mixed analyst commentary, with some emphasizing balance sheet clean up and others highlighting dilution, funding risks, and a suspended rating that underscores ongoing uncertainty. As you read on, you will see how these moving pieces shape the evolving story around Gossamer Bio and what to watch as the...